Chronic Prototheca Meningitis

Takaki, Koji; Okada, Kenji; Umeno, Morio; Tanaka, Masahito; Takeda, Tomoki; Ohsaki, Kayoko; Takaki, Y.; Sawae, Yoshinori

doi:10.3109/00365549609027183

Cited by 25 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Itraconazole (400 mg/day for 6 weeks) failed as therapy, and treatment with fluconazole at 200 mg/day improved the patient's condition (80,86). Fluconazole appears to provide clinical efficacy somewhat superior to that of itraconazole despite the high MICs obtained in vitro (15,92,144). In accordance with the results of drug susceptibility tests, one patient was treated with amikacin combined with tetracycline and responded well to this therapy (169).…”

Section: Treatmentmentioning

confidence: 82%

“…Dissemination occurs in individuals who are severely immunocompromised. Uncommon presentations, such as urinary tract protothecosis (156), colpitis (61), respiratory tract protothecosis (56), choroiditis (51), intestinal protothecosis (125), ungual infections (47,168), and meningitis (62,144), have been documented in the literature. Also, three cases with lung involvement have been reported, including one case of probable and two cases of autopsy-proven pulmonary infection (78,150).…”

Section: Clinical Findingsmentioning

confidence: 99%

“…The chronic presentation of protothecosis is typical for skin lesions and olecranon bursitis, yet in one patient protothecal meningitis persisted for more than 6 years despite treatment with various antifungal agents (144). Acute and fatal infections are rare and usually occur in severely immunosuppressed patients (65,78).…”

Section: Clinical Findingsmentioning

confidence: 99%

“…Five patients with cutaneous protothecosis received this combination and were successfully treated (52,61,152,157,166). Takaki et al (144) reported induction of secondary resistance during a 3-year period of therapy and clinical failure. Amphotericin B and fluconazole MICs increased from 0.39 to 3.13 and from 50 to 200 g/ml, respectively.…”

Section: Susceptibility Profilesmentioning

confidence: 99%

See 3 more Smart Citations

Human Protothecosis

2007

View full text Add to dashboard Cite

SUMMARY Human protothecosis is a rare infection caused by members of the genus Prototheca. Prototheca species are generally considered to be achlorophyllic algae and are ubiquitous in nature. The occurrence of protothecosis can be local or disseminated and acute or chronic, with the latter being more common. Diseases have been classified as (i) cutaneous lesions, (ii) olecranon bursitis, or (iii) disseminated or systemic manifestations. Infections can occur in both immunocompetent and immunosuppressed patients, although more severe and disseminated infections tend to occur in immunocompromised individuals. Prototheca wickerhamii and Prototheca zopfii have been associated with human disease. Usually, treatment involves medical and surgical approaches; treatment failure is not uncommon. Antifungals such as ketoconazole, itraconazole, fluconazole, and amphotericin B are the most commonly used drugs to date. Among them, amphotericin B displays the best activity against Prototheca spp. Diagnosis is largely made upon detection of characteristic structures observed on histopathologic examination of tissue.

show abstract

Section: Treatmentmentioning

confidence: 82%

Section: Clinical Findingsmentioning

confidence: 99%

Section: Clinical Findingsmentioning

confidence: 99%

Section: Susceptibility Profilesmentioning

confidence: 99%

See 2 more Smart Citations

Human Protothecosis

2007

View full text Add to dashboard Cite

show abstract

“…The patient was a heavy drinker and an intravenous drug user and died 5 months after diagnosis despite intensive treatment. The second case was a 20-year-old man with anemia, liver abscess and meningitis [8]. The liver abscess was cured with intravenous miconazole and AMB but P. wickerhamii could not be eliminated from CSF and the infection persisted for 6 years.…”

Section: Discussionmentioning

confidence: 99%

Meningitis due toPrototheca wickerhamii: rare case in China

et al. 2007

View full text Add to dashboard Cite

A rare case of Prototheca wickerhamii meningitis is reported in a patient without any underlying immunodeficient condition. Wet-mount microscopy and culture of cerebral spinal fluid specimens, along with temperature resistance, cycloheximide tolerance, carbohydrates assimilation, including API 20C AUX tests of the isolated etiologic agent were performed. In addition, transmission and scanning electron microscopy studies and in vitro antifungal susceptibility tests were conducted. Through the combination of these investigations, the isolate was identified as P. wickerhamii and the patient was successfully treated with intravenous amphotericin B and itraconazole. This is the first detailed report of meningitis caused by P. wickerhamii in China.

show abstract

Protothecosis

Pore

2010

Topley &Amp; Wilson's Microbiology and Microbial Infections

View full text Add to dashboard Cite

Chronic Prototheca Meningitis

Abstract: A case of chronic meningitis caused by the achloric alga Prototheca wickerhamii is described, which has persisted for more than 6 years despite treatment with various antifungal agents. For the last year no treatment has been given, but the patient has no complaints.

Cited by 25 publications

References 11 publications

Human Protothecosis

Human Protothecosis

Meningitis due toPrototheca wickerhamii: rare case in China

Protothecosis

Contact Info

Product

Resources

About